HK1203833A1 - 用於治療致癌病毒多肽陽性腫瘤的多核苷酸 - Google Patents

用於治療致癌病毒多肽陽性腫瘤的多核苷酸

Info

Publication number
HK1203833A1
HK1203833A1 HK15104469.7A HK15104469A HK1203833A1 HK 1203833 A1 HK1203833 A1 HK 1203833A1 HK 15104469 A HK15104469 A HK 15104469A HK 1203833 A1 HK1203833 A1 HK 1203833A1
Authority
HK
Hong Kong
Prior art keywords
polynucleotides
positive tumors
viral polypeptide
oncogenic viral
polypeptide positive
Prior art date
Application number
HK15104469.7A
Other languages
English (en)
Inventor
John H Lee
Daniel W Vermeer
Original Assignee
Sanford Res University Of South Dakota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Res University Of South Dakota filed Critical Sanford Res University Of South Dakota
Publication of HK1203833A1 publication Critical patent/HK1203833A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HK15104469.7A 2012-01-24 2015-05-12 用於治療致癌病毒多肽陽性腫瘤的多核苷酸 HK1203833A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261590089P 2012-01-24 2012-01-24
PCT/US2013/022696 WO2013112549A1 (en) 2012-01-24 2013-01-23 Polynucleotides for treating oncogenic viral polypeptide positive tumors

Publications (1)

Publication Number Publication Date
HK1203833A1 true HK1203833A1 (zh) 2015-11-06

Family

ID=48873849

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104469.7A HK1203833A1 (zh) 2012-01-24 2015-05-12 用於治療致癌病毒多肽陽性腫瘤的多核苷酸

Country Status (10)

Country Link
US (3) US9492526B2 (zh)
EP (2) EP3269387B1 (zh)
JP (2) JP6219849B2 (zh)
KR (1) KR102195196B1 (zh)
CN (2) CN104159607A (zh)
DK (1) DK2806889T3 (zh)
ES (1) ES2646590T3 (zh)
HK (1) HK1203833A1 (zh)
IN (1) IN2014DN06118A (zh)
WO (1) WO2013112549A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6805139B2 (ja) 2014-11-13 2020-12-23 ウニヴァシテ デ ジュネーブＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｇｅｎｅｖｅ ワクチンベクターとしての３分節型アレナウイルス
US10669315B2 (en) 2015-06-10 2020-06-02 Hookipa Biotech Gmbh HPV vaccines
LT3371316T (lt) 2015-11-04 2022-11-25 Hookipa Biotech Gmbh Vakcinos nuo hepatito b viruso
JP7157662B2 (ja) 2015-11-12 2022-10-20 ホオキパ バイオテック ジーエムビーエイチ 癌ワクチンとしてのアレナウイルス粒子
EP3400004A1 (en) 2016-01-08 2018-11-14 Vaccibody AS Therapeutic anticancer neoepitope vaccine
GB201605210D0 (en) * 2016-03-29 2016-05-11 Oxford Immunotec Ltd Assay
US20190134195A1 (en) * 2016-06-03 2019-05-09 Etubics Corporation Compositions and methods for the treatment of human papillomavirus (hpv)-associated diseases
CN106655327A (zh) * 2016-10-18 2017-05-10 云南中烟工业有限责任公司 一种压缩式充电装置
CN117370603A (zh) 2016-11-11 2024-01-09 谷歌有限责任公司 基于用户装置的消费模式来修改视频内容在用户装置上的呈现的方法、系统和介质
IL314393A (en) * 2018-03-06 2024-09-01 Precigen Inc Human papillomavirus vaccines and their uses
KR102712588B1 (ko) * 2020-05-25 2024-10-02 (주)진매트릭스 사람 파필로마바이러스의 구조적으로 변형된 키메라 폴리펩타이드 및 그 폴리펩타이드를 포함하는 재조합 단백질 및 그 단백질의 용도
CA3178325A1 (en) * 2020-05-25 2021-12-02 Soo Ok Kim Structurally modified chimeric polypeptide of human papillomavirus, recombinant protein comprising same polypeptide, and use of same protein

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
WO1999061608A2 (en) * 1998-05-26 1999-12-02 Institute Of Molecular And Cell Biology Polypeptides from creb binding protein and related protein p300 for use in transcriptional regulation
JP4755422B2 (ja) * 2002-10-03 2011-08-24 ワイス・ホールディングズ・コーポレイション ヒトパピローマウイルス・ポリペプチドおよび免疫原性組成物
AR065075A1 (es) * 2007-05-15 2009-05-13 Transgene Sa Vectores para la expresion multiple de genes
CA2760310A1 (en) 2009-04-28 2010-11-11 The Johns Hopkins University Compositions and methods for enhancing antigen-specific immune responses
CN102002105B (zh) * 2009-09-03 2013-01-23 中国疾病预防控制中心病毒病预防控制所 Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途

Also Published As

Publication number Publication date
US9492526B2 (en) 2016-11-15
JP6655051B2 (ja) 2020-02-26
US20180237477A1 (en) 2018-08-23
WO2013112549A1 (en) 2013-08-01
ES2646590T3 (es) 2017-12-14
US20160376324A1 (en) 2016-12-29
JP6219849B2 (ja) 2017-10-25
IN2014DN06118A (zh) 2015-08-14
DK2806889T3 (da) 2017-11-20
EP2806889A1 (en) 2014-12-03
CN104159607A (zh) 2014-11-19
EP3269387A1 (en) 2018-01-17
US9969779B2 (en) 2018-05-15
EP3269387B1 (en) 2019-07-17
US20150023996A1 (en) 2015-01-22
EP2806889A4 (en) 2016-04-20
JP2015506179A (ja) 2015-03-02
JP2018038405A (ja) 2018-03-15
KR102195196B1 (ko) 2020-12-28
KR20140131929A (ko) 2014-11-14
CN110042110A (zh) 2019-07-23
EP2806889B1 (en) 2017-08-16

Similar Documents

Publication Publication Date Title
HK1203833A1 (zh) 用於治療致癌病毒多肽陽性腫瘤的多核苷酸
IL289300A (en) Combined treatment for cancer
EP2877572A4 (en) ONCOLYTIC VIRUS TREATMENT OF RESISTANT TUMORS
EP2867815A4 (en) TECHNIQUES FOR SHORT-RANGE MUTUAL AUTHENTICATION VALIDATED BY THE USER
HK1209134A1 (zh) 非天然共有白蛋白結合結構域
LT2901341T (lt) Protekcinių vėžio epitopų identifikavimas, skirtas vėžio gydymui
HK1211487A1 (zh) 用於人腫瘤的溶瘤脊髓灰質炎病毒
EP2838912A4 (en) PEPTIDES FOR BINDING NUCLEOTIDE TARGETS
EP2807180A4 (en) PEPTIDE AGENTS USED IN ANTICANCER THERAPY
HK1210049A1 (zh) 用於治療癌症的組合療法
EP2836813A4 (en) PLASMA PROCESSING FOR DNA BINDING
IL237835B (en) Use of polypeptides extracted from pedf to treat osteoarthritis
IL239031A0 (en) Combined therapy for the treatment of her2-positive cancers
EP2925332A4 (en) PLACENTAL IMP THERAPY AGAINST CANCER
HK1210136A1 (zh) 可用於治療癌症的巨大戟醇衍生化合物
IL238606A0 (en) CD44v6-derivative peptides for the treatment of cancer metastases
EP2934500A4 (en) COMBINATION THERAPY AGAINST CANCER
SG11201502584XA (en) Peptides and methods for treating cancer
EP2908813A4 (en) COMPOUNDS FOR TREATING RAC-GTPASE MEDIA DISORDER
EP2881123A4 (en) COMPOSITION FOR THE TREATMENT OF CANCER ASSOCIATED WITH HPV INFECTION
GB201220901D0 (en) CD44v6-derived peptides for treating pancreatic cancer
IL239231A0 (en) Combined cancer treatment
GB201220891D0 (en) CD44v6-derived peptides for treating breast cancers